Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development

Abstract

The two domains in clinical pharmacology dealing with optimizing dosing recommendations are pharmacokinetics and pharmacodynamics. However, the usefulness of these disciplines is limited if viewed in isolation. Pharmacokinetic/pharmacodynamic (PK/PD) relationships and modeling builds the bridge between these two classical disciplines of clinical pharmacology. It links the concentration‐time profile as assessed by pharmacokinetics to the intensity of observed response as quantified by pharmacodynamics. Thus, the resulting so‐called integrated PK/PD‐models allow the description of the complete time course of the desired and/or undesired effects in response to a drug therapy. PK/PD‐modeling can elucidate the causative relationship between drug exposure and response and provide a better understanding of the sequence of events that result in the observed drug effect. This information can then be used to streamline the drug development process and dose optimization. This consensus paper presents an update on the current state of PK/PD‐modeling from an academic, industrial and regulatory perspective.

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis

“…However, our statistical approach did not take into account patient-level pharmacokinetic parameters such as volume of distribution and clearance, nor potential differences in evolution of PASI score over time vs changing drug levels. Therefore, future work should focus on pharmacokinetic-pharmacodynamic modeling of the whole time course of response to ustekinumab . This modeling may be of particular relevance for biologics with more upstream targets, such as differentiation pathway cytokines as opposed to effector cytokines.…”

Organic Electronic Platform for Real‐Time Phenotypic Screening of Extracellular‐Vesicle‐Driven Breast Cancer Metastasis

“…[ 21 ] Further, our platform facilitates quantitative translation to in vivo outcomes, as it readily allows modeling of pharmacokinetic/pharmacodynamic relationships, crucial for elucidating the causative relationship between drug exposure and response. [ 88 ] Although our platform improves upon current phenotypic screening technologies, positive hits must still be screened in animal models prior to clinical trials. Here, the facile drug response modeling enabled by the platform may help inform appropriate dosage and dose timings, reducing the reliance on animal studies in line with the three Rs principle for more ethical animal testing.…”

The importance of the clinical trialing process in the development of modern-day drugs

“…Researchers during the clinical trialing process then use allometric scaling to convert the NOAEL to a human equivalent dose. The second option is pharmacokinetic/pharmacodynamic modeling (PK/PD modeling), which through simulation, can produce a quantitative framework that illustrates the relationship between the drug's exposure and response, and the events that occur in the observed drug effect respectively [16] . In other words, PK/PD modeling helps architect a bridge between these two standard disciplines of clinical pharmacology, and from there can be used to optimize not only a safe starting dose, but to help determine a dosing range that can be utilized in escalation steps later in the clinical study.…”